Omnicell (OMCL) Expected to Announce Earnings on Thursday

Omnicell (NASDAQ:OMCL) is projected to issue its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect Omnicell to post earnings of $0.47 per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:30 AM ET.

Omnicell Stock Down 1.8%

Omnicell stock opened at $49.04 on Thursday. The firm has a market cap of $2.20 billion, a PE ratio of 114.05, a P/E/G ratio of 5.32 and a beta of 0.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The firm’s 50 day moving average price is $44.98 and its two-hundred day moving average price is $36.20.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 2.52% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Mariner LLC bought a new stake in shares of Omnicell during the 3rd quarter worth $388,000. Brevan Howard Capital Management LP increased its position in shares of Omnicell by 40.3% during the third quarter. Brevan Howard Capital Management LP now owns 12,195 shares of the company’s stock valued at $371,000 after buying an additional 3,501 shares during the period. Creative Planning grew its position in shares of Omnicell by 56.8% in the 3rd quarter. Creative Planning now owns 14,727 shares of the company’s stock worth $448,000 after buying an additional 5,337 shares during the period. Vident Advisory LLC bought a new position in Omnicell during the 3rd quarter valued at approximately $569,000. Finally, Headlands Technologies LLC grew its holdings in shares of Omnicell by 1,865.0% during the second quarter. Headlands Technologies LLC now owns 18,137 shares of the company’s stock valued at $533,000 after buying an additional 17,214 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on OMCL. Wells Fargo & Company raised their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Benchmark raised their price objective on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. UBS Group set a $53.00 price objective on Omnicell in a report on Friday, January 16th. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research report on Thursday, January 22nd. Finally, KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a report on Wednesday, January 7th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $48.57.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.